S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82

Neoleukin Therapeutics Stock Forecast, Price & News

+0.42 (+8.50%)
(As of 11/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
782,751 shs
Average Volume
210,300 shs
Market Capitalization
$227.41 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive NLTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Neoleukin Therapeutics logo

About Neoleukin Therapeutics

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.


Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Short Interest Update
November 30, 2021 |  americanbankingnews.com
Neoleukin Therapeutics, Inc. (NLTX)
October 15, 2021 |  ca.finance.yahoo.com
Friday 8/27 Insider Buying Report: NLTX, CYXT
August 27, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$25 million
Book Value
$3.65 per share


Net Income
$-33.28 million
Pretax Margin




Free Float
Market Cap
$227.41 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.87 out of 5 stars

Medical Sector

745th out of 1,390 stocks

Pharmaceutical Preparations Industry

354th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Neoleukin Therapeutics (NASDAQ:NLTX) Frequently Asked Questions

Is Neoleukin Therapeutics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neoleukin Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Neoleukin Therapeutics stock.
View analyst ratings for Neoleukin Therapeutics
or view top-rated stocks.

How has Neoleukin Therapeutics' stock price been impacted by COVID-19?

Neoleukin Therapeutics' stock was trading at $7.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NLTX shares have decreased by 32.7% and is now trading at $5.36.
View which stocks have been most impacted by COVID-19

Are investors shorting Neoleukin Therapeutics?

Neoleukin Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 836,100 shares, a decrease of 47.4% from the October 31st total of 1,590,000 shares. Based on an average daily volume of 199,700 shares, the short-interest ratio is presently 4.2 days. Currently, 2.6% of the shares of the company are short sold.
View Neoleukin Therapeutics' Short Interest

When is Neoleukin Therapeutics' next earnings date?

Neoleukin Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Neoleukin Therapeutics

How were Neoleukin Therapeutics' earnings last quarter?

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.28).
View Neoleukin Therapeutics' earnings history

What price target have analysts set for NLTX?

3 brokers have issued 1-year price targets for Neoleukin Therapeutics' shares. Their forecasts range from $18.00 to $22.00. On average, they anticipate Neoleukin Therapeutics' stock price to reach $20.33 in the next twelve months. This suggests a possible upside of 279.4% from the stock's current price.
View analysts' price targets for Neoleukin Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Neoleukin Therapeutics' key executives?

Neoleukin Therapeutics' management team includes the following people:
  • Jonathan G. Drachman, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Robert Ho, Chief Financial & Accounting Officer
  • Umut Ulge, Vice President-Clinical Development
  • Daniel-Adriano Silva, Vice President-Research
  • Priti Patel, Chief Medical Officer

What other stocks do shareholders of Neoleukin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neoleukin Therapeutics investors own include Alibaba Group (BABA), Cisco Systems (CSCO), Pfizer (PFE), Raytheon Technologies (RTX), Honeywell International (HON), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), CVS Health (CVS), Fulcrum Therapeutics (FULC) and Home Depot (HD).

What is Neoleukin Therapeutics' stock symbol?

Neoleukin Therapeutics trades on the NASDAQ under the ticker symbol "NLTX."

Who are Neoleukin Therapeutics' major shareholders?

Neoleukin Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.29%), Opaleye Management Inc. (2.47%), Point72 Asset Management L.P. (2.36%), EcoR1 Capital LLC (2.03%), Candriam Luxembourg S.C.A. (2.02%) and Renaissance Technologies LLC (1.78%). Company insiders that own Neoleukin Therapeutics stock include Bros Advisors Lp Baker, Carl Walkey, Jonathan G Drachman, Jonathan G Drachman, Redmile Group, Llc and Robert Ho.
View institutional ownership trends for Neoleukin Therapeutics

Which institutional investors are selling Neoleukin Therapeutics stock?

NLTX stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Opaleye Management Inc., Goldman Sachs Group Inc., Granahan Investment Management Inc. MA, Citigroup Inc., Morgan Stanley, Dimensional Fund Advisors LP, and New York State Common Retirement Fund. Company insiders that have sold Neoleukin Therapeutics company stock in the last year include Carl Walkey, and Robert Ho.
View insider buying and selling activity for Neoleukin Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Neoleukin Therapeutics stock?

NLTX stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Renaissance Technologies LLC, Millennium Management LLC, Citadel Advisors LLC, Point72 Asset Management L.P., Two Sigma Advisers LP, Two Sigma Investments LP, and GSA Capital Partners LLP. Company insiders that have bought Neoleukin Therapeutics stock in the last two years include Bros Advisors Lp Baker, Jonathan G Drachman, and Redmile Group, Llc.
View insider buying and selling activity for Neoleukin Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Neoleukin Therapeutics?

Shares of NLTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neoleukin Therapeutics' stock price today?

One share of NLTX stock can currently be purchased for approximately $5.36.

How much money does Neoleukin Therapeutics make?

Neoleukin Therapeutics has a market capitalization of $227.41 million and generates $25 million in revenue each year. The company earns $-33.28 million in net income (profit) each year or ($1.06) on an earnings per share basis.

How many employees does Neoleukin Therapeutics have?

Neoleukin Therapeutics employs 70 workers across the globe.

What is Neoleukin Therapeutics' official website?

The official website for Neoleukin Therapeutics is www.neoleukin.com.

Where are Neoleukin Therapeutics' headquarters?

Neoleukin Therapeutics is headquartered at 1616 EASTLAKE AVE EAST SUITE 360, SEATTLE WA, 98102.

How can I contact Neoleukin Therapeutics?

Neoleukin Therapeutics' mailing address is 1616 EASTLAKE AVE EAST SUITE 360, SEATTLE WA, 98102. The company can be reached via phone at (866) 245-0312, via email at [email protected], or via fax at 778-331-4486.

This page was last updated on 12/1/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.